Patents Represented by Attorney, Agent or Law Firm Nelsen L. Lentz
  • BACE inhibitors
    Patent number: 8278441
    Abstract: The present invention provides BACE inhibitors of Formula I: methods for their use, intermediates, and methods for their preparation.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: October 2, 2012
    Assignee: Eli Lilly and Company
    Inventors: Dustin James Mergott, Grant Mathews Vaught
  • Substituted carboxamides
    Patent number: 7960419
    Abstract: This application relates to a substituted carboxamide compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein, a pharmaceutical composition thereof, and its use in treating pain.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: June 14, 2011
    Assignee: Eli Lilly and Company
    Inventors: Ryan Thomas Backer, Matthew Joseph Fisher, Sean Patrick Hollinshead, Steven Lee Kuklish, Edward C R Smith, Kumiko Takeuchi
  • Oral 2-methyl-thieno-benzodiazepine formulation
    Patent number: 7229643
    Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: George Randall Cochran, Tommy Clifford Morris
  • Combination therapy for treatment of refractory depression
    Patent number: 6960577
    Abstract: Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: November 1, 2005
    Assignee: Eli Lilly and Company
    Inventor: Gary Dennis Tollefson
  • Cyclopentyl sulfonamide derivatives
    Patent number: 6900353
    Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: May 31, 2005
    Assignee: Eli Lilly and Company
    Inventors: Buddy Eugene Cantrell, Winton Dennis Jones, Jr., Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulfonamide derivatives
    Patent number: 6803484
    Abstract: The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: October 12, 2004
    Assignee: Eli Lilly and Company
    Inventors: James Abraham Aikins, Andrew Hendley Fray, William David Miller
  • Oral 2-methyl-thieno-benzodiazepine formulation
    Patent number: 6780433
    Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: August 24, 2004
    Assignee: Eli Lilly and Company
    Inventors: George Randall Cochran, Tommy Clifford Morris
  • Sulfonamide derivatives
    Patent number: 6720357
    Abstract: The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: October 17, 2002
    Date of Patent: April 13, 2004
    Assignee: Eli Lilly and Company
    Inventors: Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulphonamide derivatives
    Patent number: 6713516
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulfonamide derivatives
    Patent number: 6703425
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: March 9, 2004
    Assignee: Eli Lilly and Company
    Inventors: James Allen Knobelsdorf, Timothy Alan Shepherd, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulphonamide derivatives
    Patent number: 6693137
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 17, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Buddy Eugene Cantrell, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Edward C. R. Smith, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Cyclopentyl sulfonamide derivatives
    Patent number: 6639107
    Abstract: The present invention provides certain cyclopentyl sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a mammal. It also relates to novel cyclopentyl sulfonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: James Abraham Aikins, Edward C R Smith, Timothy Alan Shepherd, Dennis Michael Zimmerman
  • Amide, carbamate, and urea derivatives
    Patent number: 6617351
    Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • 2-methyl-thieno-benzodiazepine formulation
    Patent number: 6617321
    Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation or olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Douglas J. Allen, Kurt D. Dekemper, Thomas H. Ferguson, Stuart J. Garvin, Linda C. Murray, Norman D. Brooks, Charles A. Bunnell, Snehlata S. Mascarenhas, Sharon L. Shinkle, Barry A. Hendriksen, David E. Tupper, Manuel V. Sanchez-Felix
  • 2-propane-sulphonamide derivatives
    Patent number: 6596716
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain 2-propane-sulphonamide derivatives. It also relates to novel 2-propane-sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: July 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Tracey E McKennon, Paul L Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M Zimmerman
  • Selective iglur5 receptor antagonists
    Patent number: 6579886
    Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: June 17, 2003
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael Edward Le Tourneau, Michael John Martinelli, Mark Alan Winter
  • Sulfonamide derivatives
    Patent number: 6552086
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: April 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • N-substituted sulfonamide derivatives
    Patent number: 6525099
    Abstract: The present invention provides certain N-substituted sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 25, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Amidophosphate derivatives
    Patent number: 6521605
    Abstract: The present invention provides amidophosphate derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 18, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Process for preparing 2-methyl-thieno-benzodiazepine
    Patent number: RE40033
    Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Reba Chakrabarti, Terrence Michael Hotten, David Edward Tupper, Jiban Kumar Chakrabarti